Sionna Therapeutics

Q2 FY2026 EarningsQ2 FY26 results slightly missed consensus on the bottom line, with a GAAP EPS of -$0.66 vs. the -$0.65 expected. Net loss of $29.9M was wider than the $29.2M consensus due to higher-than-expected operating expenses as clinical programs accelerated. However, the company maintained a robust cash position of $268.3M, providing a runway into 2028, and reaffirmed that topline data for both its Phase 2a and Phase 1 trials remain on track for Summer 2026.